News
NANOBIOTIX Provides Third Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2021
POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis’ senior management
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Savara to Present at the Inaugural Piper Sandler Lung Day
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the
Quantum Genomics and its partners reach a new stage of development in Asia
Quantum Genomics and its partners reach a new stage of development in Asia
- The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced the
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity
Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity
- Firibastat expected to launch in late 2023 for difficult-to-treat/resistant hypertension.
- Gross cash of €24.9
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts
Poxel Announces its Participation at Investor Conferences in October 2021
Regulatory News:
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanophysics-based approaches to expand treatment
Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Neuer Deal und weitere Großmaschine verkauft! EnWave gibt weiter mächtig Gas!
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
EnWave is back - und zwar stärker denn je!